成都先导(688222.SH)：预计2025年净利润同比增加102.50%到147.29%

Group 1 - The company expects a net profit attributable to shareholders of the parent company for 2025 to be between 104 million to 127 million yuan, representing a year-on-year increase of 102.50% to 147.29% [1] - The expected net profit attributable to shareholders of the parent company, after deducting non-recurring gains and losses, is projected to be between 106 million to 129 million yuan, reflecting a year-on-year increase of 84.55% to 124.59% [1] Group 2 - The core business segment, DEL, which includes design, synthesis, and screening of DEL libraries, has maintained steady growth and high gross margins, contributing to overall profit improvement [2] - The UK subsidiary has further solidified the steady development of the FBDD/SBDD platform, with milestone revenues achieved from client projects in both DEL and FBDD/SBDD [2] - The OBT segment has shown significant revenue growth by expanding traditional nucleotide monomer synthesis and achieving commercial transformation of small nucleic acid projects [2] - The automated high-throughput chemical synthesis platform designed and built by the company has operated efficiently, driving revenue growth in ChemSer services [2]